X
Search
X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

CareFirst BlueCross BlueShield Announces Coverage of New Liquid Biopsy Tests for Prostate Cancer

CareFirst BlueCross BlueShield (CareFirst) announced that it has reached a positive coverage decision for the ExoDx® Prostate(IntelliScore) or EPI test – meaning that the test will be covered for CareFirst members beginning in 2018. This coverage decision is based in part on results from an evidence development study conducted as part of a collaboration between CareFirst and Exosome Diagnostics – the developer of the EPI test. The EPI test improves both cost and quality outcomes for patients, helping urologists assess whether an individual presenting for an initial prostate biopsy is at greater risk for high-grade cancer and avoiding the cost and complications associated with unnecessary prostate biopsies as well as overtreatment of low-risk prostate cancer. Thus, it can improve care outcomes for CareFirst members and lower costs at the same time.

Read more.

source: CareFirst BlueCross BlueShield